Chiesi Farmaceutici S.p.a.

David Edward Clark

Fabio Rancati

Christine Edwards

Anna Maria Capelli

Alessandro Accetta

Patrizia Tisselli

Gurdip Bhalay

Arnaud Jean Francois Auguste Cheguillaume

Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Tyrosine amide derivatives as Rho-Kinase inhibitors

Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and pulmonary arterial hypertension (PAH).

Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-Kinase inhibitors

Tyrosine amide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Tyrosine amide derivatives as Rho-kinase inhibitors

Growing community of inventors

Saffron Walden, United Kingdom

David Edward Clark